Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215
J Immunol. 2021 Apr 15;206(8):1719-1728. doi: 10.4049/jimmunol.2001266. Epub 2021 Mar 24.
Protein phosphatase 2A (PP2A) composed of a scaffold subunit, a catalytic subunit, and multiple regulatory subunits is a ubiquitously expressed serine/threonine phosphatase. We have previously shown that the PP2A catalytic subunit is increased in T cells from patients with systemic lupus erythematosus and promotes IL-17 production by enhancing the activity of Rho-associated kinase (ROCK) in T cells. However, the molecular mechanism whereby PP2A regulates ROCK activity is unknown. In this study, we show that the PP2A regulatory subunit PPP2R2A is increased in T cells from people with systemic lupus erythematosus and binds to, dephosphorylates, and activates the guanine nucleotide exchange factor GEF-H1 at Ser, which in turn increases the levels of RhoA-GTP and the activity of ROCK in T cells. Genetic PPP2R2A deficiency in murine T cells reduced Th1 and Th17, but not regulatory T cell differentiation and mice with T cell-specific PPP2R2A deficiency displayed less autoimmunity when immunized with myelin oligodendrocyte glycoprotein peptide. Our studies indicate that PPP2R2A is the regulatory subunit that dictates the PP2A-directed enhanced Th1 and Th17 differentiation, and therefore, it represents a therapeutic target for pathologies linked to Th1 and Th17 cell expansion.
蛋白磷酸酶 2A(PP2A)由支架亚基、催化亚基和多个调节亚基组成,是一种广泛表达的丝氨酸/苏氨酸磷酸酶。我们之前已经表明,系统性红斑狼疮患者的 T 细胞中 PP2A 催化亚基增加,并通过增强 T 细胞中 Rho 相关激酶(ROCK)的活性来促进 IL-17 的产生。然而,PP2A 调节 ROCK 活性的分子机制尚不清楚。在这项研究中,我们表明,PP2A 调节亚基 PPP2R2A 在系统性红斑狼疮患者的 T 细胞中增加,并与 GEF-H1 结合,使其丝氨酸去磷酸化并激活 GEF-H1,从而增加 T 细胞中 RhoA-GTP 的水平和 ROCK 的活性。在鼠 T 细胞中遗传 PPP2R2A 缺陷减少了 Th1 和 Th17,但不减少调节性 T 细胞的分化,并且在髓鞘少突胶质细胞糖蛋白肽免疫时,具有 T 细胞特异性 PPP2R2A 缺陷的小鼠显示出较少的自身免疫。我们的研究表明,PPP2R2A 是决定 PP2A 介导的 Th1 和 Th17 分化增强的调节亚基,因此,它是与 Th1 和 Th17 细胞扩增相关的病理的治疗靶点。